Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2026-01-01 @ 6:32 AM
Study NCT ID:
NCT04837508
Status:
UNKNOWN
Last Update Posted:
2021-12-10
First Post:
2021-04-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
Sponsor:
Shanghai Miracogen Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-08
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-06
First Submit QC Date:
None
Study First Post Date:
2021-04-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-12-08
Last Update Post Date:
2021-12-10
Last Update Post Date Type:
ACTUAL